[go: up one dir, main page]

WO2006095359A1 - Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof - Google Patents

Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof Download PDF

Info

Publication number
WO2006095359A1
WO2006095359A1 PCT/IN2005/000160 IN2005000160W WO2006095359A1 WO 2006095359 A1 WO2006095359 A1 WO 2006095359A1 IN 2005000160 W IN2005000160 W IN 2005000160W WO 2006095359 A1 WO2006095359 A1 WO 2006095359A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
product
chloride
toluene
deoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2005/000160
Other languages
French (fr)
Inventor
Ramesh Babu Potluri
Hariharakrishnan Venkata Subramanian
Ramesh Betini
Satyanarayana Gunturu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SMS Pharmaceuticals Ltd
Original Assignee
SMS Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SMS Pharmaceuticals Ltd filed Critical SMS Pharmaceuticals Ltd
Publication of WO2006095359A1 publication Critical patent/WO2006095359A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical

Definitions

  • the invention relates to the filed of chemistry and more particularly relates to the synthesis of 2-deoxy-2,2-di fluoro-D-ribo furanose - 3,5 di (4-me ⁇ hyl / 4-nitro/4- chloro) benzoate and its conversion to Gemcitabine, HCI thereof.
  • Furanosyl nucleosides like Cytarabine and Zalcitabine have been used for the treatment of acute mylogenous leukemia. Introducing fluorine into nucleosides has also proved to be useful procedure for modifying the biological activity of these compounds.
  • Gemcitabine a 2'-deoxy-2 ,2'-difluoro nucleoside has proved to be highly active against cancer and has been used for treating several types of tumors.
  • the product of formula V was reduced to give iactol derivative of formula Va and then mesylated to give a product of formula Vl.
  • the mesylate, of formula Vl was coupled with bissilyl acetyl cytosine to give the protected nucleoside, which was hydrolyzed, converted into hydrochloride salt and crystallized to give Gemcitabine HCI of greater than 99% purity.
  • One of the objective of the present invention is to prepare a novel derivative similar to di benzoate of fomula-V Viz diaroyl derivative of formula Vb , which can be isolated and easily purified .
  • Another objective is to convert the lactone derivative of formula Vb to lactol derivative by using a reagent, which is cheaper and easier to handle.
  • Yet another objective of the invention is to develop a methodology , which results in Gemcitabine hydrochloride of extra high purity.
  • the invention describes a new process for the manufacture of high pure Gemcitabine hydrochloride of formula I
  • R is CH 3 -CI, NO 2
  • R' is CH 3 SO 2 , C 6 H 5 SO 2 ⁇ -CH 3 -C 6 H 4 SO 2 etc
  • the product of formula - VII was reacted with an aroyl chloride like p- toluoyl chloride, p-chloro benzoyl chloride, p-nitro benzoyl chloride etc in the presence of an organic base like pyridine, picolines etc.
  • the reaction was preferably conducted in the presence of a promoter like 4-dimethyl amino pyridine.
  • the reaction was conducted more preferably at a temperature of 60 - 70° C and the progress of the reaction was followed by TLC.
  • the solvent systems tried were mixture of benzene, toluene, xylene, fluoro benzene etc and hexane, petroleum ether/ heptane, cyclohexane etc. It was preferable to use a mixture of toluene or fluoro benzene with hexane, heptane, cyclohexane etc.
  • the residue after aroylation, with the respective aroyl chloride, was dissolved in about 6 to 8 volumes of the aromatic solvent and subjected to azeotropic distillation. It was preferably concentrated completely and then the residue was again dissolved in 4 to 6 volumes of the aromatic solvent.
  • the solution was warmed to 60 - 80° C and with stirring was diluted with an equal volume of the alkane VIZ petroleum ether, hexane, heptane, cyclohexane etc.
  • the diaroyl derivative precipitated in good yield and excellent purity (>99% by HPLC).
  • the yield of the diaroyl derivative was about 25%.
  • reaction was preferably conducted at -10° to +20 0 C.
  • the progress of the reaction mixture was monitored by HPLC(Zorbax CN hexane and isopropylakcohol 92:8 at ⁇ 254).
  • the product showed up as two peaks.
  • the product obtained as described above was converted into a product of formula - Vib by reacting with aliphatic/aromatic sulphonyl chloride.
  • This reaction was conducted preferably in a solvent like dichloro methane dichloroethane, ethyiacetate etc using triethylamine or diisopropylethylamine or N- methyl morpholine as the acid scavenger.
  • the progress of the reaction was monitored by HPLC(Zorbax CN hexane: isopropyl alcohol 92:8 ⁇ 254).
  • the product showed up as two peaks.
  • the reaction mixture was worked up and the product obtained was used for coupling with bis silyl acetyl cytosine.
  • Acetyl cytosine was converted into bissilyl acetyl cytosine by treatment with hexa methyl disilazane before it was subjected to coupling with product of product of Vl b.
  • the reaction was conducted preferably in the presence of trimethyl silyltri fluoro methane sulfonate.
  • Several other reagents like SnCI 4 , ZnCI 2 etc. were also tried but the yields were not very good.
  • the coupling reaction was tried in several solvents like benzene, toluene, xylene, fluoro benzene, methylenechloride.dichloro ethane, ethylacetate, acetonitrile, etc.
  • the product obtained on coupling of bis silyl acetyl cytosine and the di aroyl derivative of formula VIb, was preferably deprotected in a solvent like methanol, ethanol, isopropanol, etc. in the presence of base like ammonia, mono methyl amine, dimethyl amine etc at a temperature of 0 - 30° C during a period of 15 - 20 hours.
  • the alcoholic solution was concentrated under reduced pressure, and dissolved in 2 to 4 volumes of water.
  • the aqueous solution was washed preferably with an organic solvent like ethyl acetate, hexane, etc.
  • the aqueous layer was diluted with 3 - 4 volumes of isopropyl alcohol and concentrated. This process was preferably repeated 2 to 4 times.
  • the residue obtained was again dissolved in 3 to 6 volumes of iso propyl alcohol.
  • the residue was more preferably dissolved in 4 to 6 ' volumes of iso propyl alcohol, warmed to 60 - 80° C and hydrochloric acid, 0.5 volume to that of the residue, was added.
  • the reaction mixture was preferably stirred at 65 - .75 0 C for 30 - 60 minutes, allowed to cool to room temperature under stirring and was stirred further for 10 to 16 hours. Then the reaction mixture was cooled to about 0 - 5 0 C and preferably stirred for 2 to 4 hours.
  • the precipitated solid was filtered, washed with acetone and dried.
  • the sample was ⁇ 95% rich in the ⁇ -anomer.
  • the yield at this step was ⁇ 15% starting the diaroyl derivative Vb.
  • the solid, obtained above, was further purified by first stirring with water.
  • the solid was taken in 1 to 2 volumes of water and stirred preferably for 1 - 3 hours at 15 - 30° C, filtered, washed with acetone and dried. Dissolving in water and precipitating with a solvet like acetonitrile or isopropyl alcohol or acetone further purified the product.
  • the solid was preferably dissolved in 3 to 6 volumes of water.
  • the solid was more preferably dissolved in 4 to 6 volumes of water, heated to about 60 - 70° C and filtered.
  • the filterate was diluted with one of the organic solvent mentioned earlier.
  • the ratio of water to that of the organic solvent was preferably 1 :8 to 12.
  • the ratio of water to organic solvent was more preferably 1 :9 to 1 1.
  • Ethyl-2,2-difluoro-3-(2,2-dimethyl dioxalan-4-yl) propionate was prepared by the methods described in the literature. The product was rich in R-isomer by about 75% and this product was used in the following reactions
  • reaction mixture wis stirred at 60 0 C to 65 0 C for about 3 hours and then cooled to 25 0 C to 30 0 C and filtered through a bed of hyflow. Then the hyflow bed was washed with 200 ml ethyl acetate.
  • the combained extract was successively washed with 300 ml each of 10%hydrochloric acid, 10% sodium bicarbonate, saturated sodiumchloride solution and finally dried over anhydrous sodium sulphate
  • the ethylacetate solution was filtered and concentrated under reduced pressure. The residue was dissolved in 150 ml toluene and transferred into a three-necked round bottom flask fitted with a stirrer, addition funnel and a thermometer socket.
  • the reaction mixture was analyzed byTLC (Mobile phase-Ethyl acetate: Pet. Ether: 2:8). It was also analyzed by HPLC in zarboax CN using hexane + isopropyl alcohol 92ml + 8ml which indicated the product as two peaks.
  • the reaction mixture was washed with 5% aqueous sodium bicarbonate solution, 325ml, saturated sodium chloride solution 325ml and separated.
  • the toluene extract was dried over anhydrous sodium sulphate, filtered and then concentrated to give 100 gms of the title product. This was used for the Verbruggen protocol.
  • Example- 4 Preparation of 2'-Deoxy-2',2'-difluoro cytidine(I)
  • a stirrer, condenser and a stopper acetyl cytosine 97.36gms, toluene 2lit, hexamethyl disilazane 169ml and trimethyl silyl chloride 5ml were charged and the reaction mixture was heated to reflux under stirring. The reaction mixture slowly attained clarity and from that point the mixture was stirred at reflux for another 3 hours.
  • the progress of the reaction was monitored by TLC (dichloromethane: methanol 9:1).
  • the reaction mixture was cooled to 20 0 C to 25 0 C and 5% aqueous hydrochloric acid, 600ml, was added dropwise in about 30minutes. After the addition, the reaction mixture was stirred for 15minutes and allowed the layers to separate.
  • the aqueous layer was washed with toluene 2000ml and the combined toluene 9 extract was washed with a saturated solution of sodium chloride, 300ml. Then the organic layer was separated and dried with anhydrous sodium sulphate.
  • the fluoro benzene solution was filtered and concentrated under reduced pressure at 50 0 C.
  • the residue was dissolved in 1.5lit methanol and cooled to about 0 0 C to 5 0 C. Ammonia gas was bubbled into the methanolic solution for about 8 hours. Then the solution was brought to about 20 0 C to 25 0 C and ammonia gas was bubbled for further 8 hours. The progress of the reaction reaction was monitored by TLC for completion. The methanolic solution was treated with carbon, 15gms and filtered. The filtrate was concentrated under reduced pressure at 45 0 C. The residue was dissolved in about 400ml Water and the aqueous solution was washed first with 100ml ethyl acetate and then with 100ml hexane .
  • the ethyl acetate and hexane extracts were separately washed with 50ml each of water and the water extracts were combined with the main aqueous solution.
  • the aqueous extract was stirred with carbon, 10gm, and filtered through a bed of hyflow.The hyflow bed was washed with water, 50ml.
  • the combined aqueous solution was then concentrated.
  • the residue was dissolved in 1500ffil isopropyl alcohol and then the solution was subjected to distillation.
  • the addition of isopropyl alcohol and distillation was repeated two more times by adding 750ml of alcohol each time.
  • isopropyl alcohol, 700ml was added to the residue and the solution was warmed to about 70 0 C.
  • Method A About 50gms of the product of about 95% rich in ⁇ -anomer was stirred with 50ml DM water at 30 0 C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give40.0 gm of product.
  • the solid obtained above was taken in about 188 ml water in a 250 ml three- necked round bottom flask fitted with a stirrer, condenser and a stopper.
  • the slurry was heated to 70 0 C to 75 0 C in order to dissolve the solid:
  • the solution was filtered to remove any insoluble material and the filtrate was transferred into a 3 lit three- necked flask fitted with a stirrer, addition funnel and stopper.
  • the aqueous solution was stirred at 25 0 C to 30 0 C and acetone2.3 lit, was added dropwise from the addition funnel. After the completion of addition the slurry was stirred at 25 0 C to 3.0 0 C for 1 hour and the solid was filtered. It was washed'with acetone and dried at 60 0 C to give 36.0 gm of very pure product.
  • Method B About 50gms of the product of about 95% rich in ⁇ -anomer, was stirred with 50ml DM water at 30 0 C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give gms of product
  • the solid obtained above was taken in about 190 ml of water in a 250 ml three-necked round bottom flask fitted with a stirrer, condenser and a stopper.
  • the slurry was heated to about 70 0 C to 75 0 C in order to dissolve the solid.
  • the solution was filtered to remove any insoluble material and the filtrate was transferred into a 3lit three-necked round bottom flask fitted with a stirrer, addition funnel and stopper.
  • the aqueous solution was stirred at 25 0 C to 30 0 C and 3 lit acetonitrile was added dropwise from the addition funnel. After the completion of addition the slurry was stirred at 25 0 C to 3O 0 C and the solid was filtered, washed with acetone, pressed dry and dried 60 0 C to give 36 gm of very pure product.
  • Method C About 50gms of the product about 95% rich ⁇ -anomer was stirred with 50ml DM water at 30 0 C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give 40 gm of product.
  • the solid obtained above was later dissolved in about 188 ml water in a 250 ml three-necked round bottom flask fitted with a stirrer, condenser and a stopper.
  • the slurry was heated to about 70 0 C to 75 0 C ⁇ n order to dissolve the solid.
  • the solution was filtered to remove any insoluble material and the filtrate was transferred into a 3 lit three necked round bottom flask fitted with a stirrer, addition funnel and stopper.
  • the aqueous solution was stirred at 25 0 C to 30 0 C and isopropyl alcohol 2.3 lits was added dropwise from the addition funnel.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention describes the synthesis of hereto unreported 2-deoxy-2,2-difluoro-D-ribofuranose-3,5-di-(aroyl) derivative of formula-Vb, where in R=;CH3,CI,NO2 and its conversion to Gemcitabine HCl of formula-I, an anti cancer product.

Description

DESCRIPTION OF THE INVENTION: Field of invention:
The invention relates to the filed of chemistry and more particularly relates to the synthesis of 2-deoxy-2,2-di fluoro-D-ribo furanose - 3,5 di (4-meϊhyl / 4-nitro/4- chloro) benzoate and its conversion to Gemcitabine, HCI thereof.
References Cited
US Pat.No 4526988 US Pat.No 4808614 US Pat No 5233608 US Pat No 5945547 EP Pat No 306190 Other References Synthesis 565-570 1992
BACKGROUND OF THE INVENTION:
Furanosyl nucleosides like Cytarabine and Zalcitabine have been used for the treatment of acute mylogenous leukemia. Introducing fluorine into nucleosides has also proved to be useful procedure for modifying the biological activity of these compounds. Gemcitabine, a 2'-deoxy-2 ,2'-difluoro nucleoside has proved to be highly active against cancer and has been used for treating several types of tumors.
The synthesis of Gemcitabine has been described in many patents.The basic chemistry approach has remained same.except variations in the protecting groups and improvements in the purification methodology. The synthesis as described in US Pat Nos 4526988 and 4808614 is given in scheme-l
Figure imgf000003_0001
Formula - Il Formula - III Formula - IV
Figure imgf000003_0002
Formula - IX Formula - VIII Formula - VII
Figure imgf000003_0003
Formula - X Formula -
Scheme-l
In this process, (R )-2,3-O-isopropylidene carboxaldehyde was treated with ethyl bromo difluoro acetate under Reformatsky conditions to yield the product of formula IV, which contained R and S isomers in the ratio 3:1 and this mixture was purified by column chromatography to get the pure R-isomer. This product was hydrolytically cyclized using ion-exchange resin to give 2-deoxy-2,2- difluoro-1-oxo ribose of formula VII, which was converted into bis-t-butyl dimethyl silylated derivative and purified by column chromatography to get a product of formula VIII. The lactone of formula VIII was reduced with DIBAL to give lactol of formula IX, which was again purified by column chromatography.
Reaction of this product with methane sulfonyl chloride in presence of a base yielded the product of formula X, which was coupled with bis silylated cytosine of formula Xl and the coupled product was deprotected and purified by preparative HPLC to get Gemcitabine HCI product of formula I The process, as described in US Pat No. 5223608, is depicted in scheme Il
Figure imgf000005_0001
Formula - Formula - Formula - IV
,-^
Figure imgf000005_0002
Formuia - V Formula - XiI! Formula - XlI
Figure imgf000005_0003
Formula - V a Formula - Vl
Figure imgf000005_0004
Formula - Xl
Figure imgf000005_0005
β - anomer
Scheme - I! The method followed in US Pat No 5223608 is similar to the one described in scheme-l upto the preparation of the .product of formula -IV This was first benzoylated without separation of R&S isomers to give a product of formula XII, which was subjected to hydrolytic cyciization to give a product of formula XIII. This product was benzoylated and purified by crystallization, preferably, from a mixture of dichloromethane and hexane/heptane or isopropyl alcohol/hexane to give a product of formula V viz. 2-deoxy-2,2-difuluoro-D-erythreo pentafuranose-1-ulose- 3,5-dibenzoate in about 95% purity.
The product of formula V was reduced to give iactol derivative of formula Va and then mesylated to give a product of formula Vl. The mesylate, of formula Vl, was coupled with bissilyl acetyl cytosine to give the protected nucleoside, which was hydrolyzed, converted into hydrochloride salt and crystallized to give Gemcitabine HCI of greater than 99% purity.
These are the two major approaches for the synthesis of Gemcitabine HCI. The method described in US Pat Nos 4526988 and 4808614 adopt laborious chromatographic purifications in different stages which make the process industrially unviable. The process described in US Pat.No.5223608 takes care of these shortcomings. In the latter procedure also, there are a few shortcomings , which are listed below a) isolation of 2-deoxy-2,2,-difluoro-D-erythropentafurano-1-ulose-3,5- dibenzoate b) reduction of the lactone of formula V to the lactol of formula Va c) isolation of the 1 :1 α/β anomers and further purification
The crude product of formula V containing the erythro and threo isomers was crystallized, preferably, from a mixture of dichloromethane and hexane. When this method was followed, there was large variation in the proportion of erythro and threo for different batches and it was tedious to get a product mixture containing 95% rich in erythrose isomer •
The reduction of formula V to the lactol of formula Va was carried out using DIBAL or tri-tertiary butoxy lithium aluminum hydride. Both these reagents are expensive and difficult to handle.
The crude Gemcitabine HCI was isolated as 1 :1 α and β anomer mixture in aqueous isopropyl alcohol and subsequently crystallized from aqueous acetone to get the product of formula I in greater than 99% purity by HPLC. Object of the invention :
One of the objective of the present invention is to prepare a novel derivative similar to di benzoate of fomula-V Viz diaroyl derivative of formula Vb , which can be isolated and easily purified .Another objective is to convert the lactone derivative of formula Vb to lactol derivative by using a reagent, which is cheaper and easier to handle.
Yet another objective of the invention is to develop a methodology , which results in Gemcitabine hydrochloride of extra high purity.
Summary of the invention :
The invention describes a new process for the manufacture of high pure Gemcitabine hydrochloride of formula I
Figure imgf000008_0001
Formula-I by the reaction of (R)2,3-o-isopropylidene glyceraldehyde of formula
Figure imgf000008_0002
Formula - 1 with ethyl bromo difluoro acetate of formula
Br-C COOC2H5
F Formula - III to give a product of formula IV,
Figure imgf000008_0003
Formula - IV
which is hydrolytically cyclized, converted into a diaroyl derivative and purified to give a product of formula Vb
Figure imgf000008_0004
Formula - Vb where R is CH31CI1NO2 Product of formula Vb is reduced and converted into a mesylate of formula VIb
Figure imgf000009_0001
Formula - Vl b
R is CH3-CI, NO2
R' is CH3SO2, C6H5SO2^-CH3-C6H4SO2 etc
which is coupled with bis trimethylsilyl acetyl cytosine of formula Xl, under Verburggen condition, hydrolyzed and isolated to give product of formula 1 in 95% purity. This is further purified to yielded a product of extra high purity of >99.8%.
Detailed description of the invention :
The method adopted in this invention is represented in the Scheme -III
Figure imgf000010_0001
IV VII
Figure imgf000010_0002
Via V b a) R=CH3, b) R=CI; c) R=NO2
Figure imgf000010_0003
Scheme-Ill Ethyl 2,2-difluoro-3-hydroxy-3-(2,2-dimethyl dioxa!an-4-yl) acetate was hydrolyticaliy cyclised to give a product of formula - VII. This reaction was carried out in acetone, acetonitrile, etc containing water and an acid like trifluoroacetic acid, sulphuric acid, benzene sulphonic acid, p-toluene sulphonic acid etc. The reaction was preferably conducted in aqueous acetone or acetonitrile using acid catalyst at a temperature of 60 - 80 C. After the maintenance for about 4 - 5 hours, the reaction mixture was subjected to distillation along with simultaneous addition of toluene and this was continued until the mass temperature was ~ 1100 C. The progress of the reaction was monitored by IR. As the reaction progressed, the >C=O stretching vibration for the starting material at 1760 Cm'1 disappeared and >C=O stretching vibration for the product appeared at 1812 Cm'1.
On completion, the reaction mixture was concentrated under reduced pressure, the residue obtained was dissolved in ethyl acetate, washed with ice- cold water, dried over anhydrous sodium sulphate and filtered. The filtrate was used for the next stage.
The product of formula - VII was reacted with an aroyl chloride like p- toluoyl chloride, p-chloro benzoyl chloride, p-nitro benzoyl chloride etc in the presence of an organic base like pyridine, picolines etc. The reaction was preferably conducted in the presence of a promoter like 4-dimethyl amino pyridine. The reaction was conducted more preferably at a temperature of 60 - 70° C and the progress of the reaction was followed by TLC. On completion, the reaction was worked up and the residue obtained was purified using a mixture di chloro methane, di chloro ethane, chloroform, etc and hexane, heptane, petroleum ether, cyclo hexane etc. The purity of the product (HPLC) was not acceptable. The product was a mixture of 80 - 85% of erythro, 15 - 20% threo .Since the purification using a mixture of dichloro methane, di chloro ethane, chloroform etc and hexane, heptane, petroleum ether, cyclo hexane etc. did not yield a product of acceptable quality, it was decided to try out other solvent systems. The solvent systems tried were mixture of benzene, toluene, xylene, fluoro benzene etc and hexane, petroleum ether/ heptane, cyclohexane etc. It was preferable to use a mixture of toluene or fluoro benzene with hexane, heptane, cyclohexane etc. The residue after aroylation, with the respective aroyl chloride, was dissolved in about 6 to 8 volumes of the aromatic solvent and subjected to azeotropic distillation. It was preferably concentrated completely and then the residue was again dissolved in 4 to 6 volumes of the aromatic solvent. The solution was warmed to 60 - 80° C and with stirring was diluted with an equal volume of the alkane VIZ petroleum ether, hexane, heptane, cyclohexane etc. On cooling the diaroyl derivative precipitated in good yield and excellent purity (>99% by HPLC). The yield of the diaroyl derivative was about 25%.
Earlier reports describe the reduction of lactone derivative of formula - Vb to the corresponding lactol derivative of formula Via using either bis-tert- butoxy lithium aluminium hydride or DIBAL. Since these reagents are expensive and difficult to handle, another objective of the invention was to utilize a reagent, which is cheaper and easier to handle. Vitride i.e Sodium bis(2-methoxy ethoxy) aluminium hydride, as a 65% w/w solution in toluene, is commercially available. This is a versatile reagent, which is cheap and easy to handle. It was decided to try the conversion of the product of formula Vb to the product of formula Via using vitride.The reaction was tried in solvents like 1 ,2 dimethoxy ethane, diethylene glycol dimethyl ether, 1 ,4-dioxane etc. It was preferable to use 1,2 di methoxy ethane, di ethylene glycol di methyl ether, THF, etc. The mole ratio of the substrate to that of the reagent was preferably
1:0.5 - 0.75 moles. The reaction was preferably conducted at -10° to +200C. The progress of the reaction mixture was monitored by HPLC(Zorbax CN hexane and isopropylakcohol 92:8 at λ 254). The product showed up as two peaks.
The product obtained as described above was converted into a product of formula - Vib by reacting with aliphatic/aromatic sulphonyl chloride. This reaction was conducted preferably in a solvent like dichloro methane dichloroethane, ethyiacetate etc using triethylamine or diisopropylethylamine or N- methyl morpholine as the acid scavenger. The progress of the reaction was monitored by HPLC(Zorbax CN hexane: isopropyl alcohol 92:8 λ 254). The product showed up as two peaks. On completion, the reaction mixture was worked up and the product obtained was used for coupling with bis silyl acetyl cytosine.
Acetyl cytosine was converted into bissilyl acetyl cytosine by treatment with hexa methyl disilazane before it was subjected to coupling with product of product of Vl b. The reaction was conducted preferably in the presence of trimethyl silyltri fluoro methane sulfonate. Several other reagents like SnCI4, ZnCI2 etc. were also tried but the yields were not very good. The coupling reaction was tried in several solvents like benzene, toluene, xylene, fluoro benzene, methylenechloride.dichloro ethane, ethylacetate, acetonitrile, etc. it was preferable to conduct the reaction in toluene, fluoro benzene, dichloroethane, ethyl acetate, acetonitrile, etc.lt was more preferably to conduct the reaction in toluene, fluoro benzene, ethylacetate etc. It was preferable to conduct the reaction at a temperature of 60 - 800 C for a duration of 10 to 20 hours. On completion of the reaction, the product was deprotected by. ' treatment with methanol containing ammonia, mono methyl amine, di methyl amine, etc. The deprotected product was converted into hydrochloride and selectively crystallized to give a product rich in >95% of β-anomer . This was further purified to give a product
of >99.8%HPLC purity.-
The product, obtained on coupling of bis silyl acetyl cytosine and the di aroyl derivative of formula VIb, was preferably deprotected in a solvent like methanol, ethanol, isopropanol, etc. in the presence of base like ammonia, mono methyl amine, dimethyl amine etc at a temperature of 0 - 30° C during a period of 15 - 20 hours. On completion, the alcoholic solution was concentrated under reduced pressure, and dissolved in 2 to 4 volumes of water. The aqueous solution was washed preferably with an organic solvent like ethyl acetate, hexane, etc. Sub -sequently the aqueous layer was diluted with 3 - 4 volumes of isopropyl alcohol and concentrated. This process was preferably repeated 2 to 4 times. The residue obtained was again dissolved in 3 to 6 volumes of iso propyl alcohol. The residue was more preferably dissolved in 4 to 6' volumes of iso propyl alcohol, warmed to 60 - 80° C and hydrochloric acid, 0.5 volume to that of the residue, was added. The reaction mixture was preferably stirred at 65 - .750 C for 30 - 60 minutes, allowed to cool to room temperature under stirring and was stirred further for 10 to 16 hours. Then the reaction mixture was cooled to about 0 - 50 C and preferably stirred for 2 to 4 hours. The precipitated solid was filtered, washed with acetone and dried. The sample was ~ 95% rich in the β-anomer. The yield at this step was ~ 15% starting the diaroyl derivative Vb.
The solid, obtained above, was further purified by first stirring with water. The solid was taken in 1 to 2 volumes of water and stirred preferably for 1 - 3 hours at 15 - 30° C, filtered, washed with acetone and dried. Dissolving in water and precipitating with a solvet like acetonitrile or isopropyl alcohol or acetone further purified the product. The solid was preferably dissolved in 3 to 6 volumes of water. The solid was more preferably dissolved in 4 to 6 volumes of water, heated to about 60 - 70° C and filtered. The filterate was diluted with one of the organic solvent mentioned earlier. The ratio of water to that of the organic solvent was preferably 1 :8 to 12. The ratio of water to organic solvent was more preferably 1 :9 to 1 1. After dilution, the mixture was stirred at 60 to 70° C for 2 to 4 hours, slowly cooled to about 20 to 25° C and further cooled to 0 - 5° C. The precipitated solid was filtered, washed with acetone and dried. The overall yield, after two purifications was The purity of Gemcitabine HCI was 99.8 to 99.9 % by HPLC The [α]D 25 = +48 (C=LO1 D2O) and mp 288 - 2890C
Thus the major achievements of the invention are :
a) synthesis of new intermediates for the preparation Gemcitabine b) utilizing a new reducing agent for the reduction of 3,5-di aroyl-2-deoxy- 2,2-di fiuoro-D-ribofurose c) Verbruggen coupling in a solvent like toluene, fluoro benzene, ethyl acetate, etc by which a class I solvent like di chloro ethane, can be avoided. d) a new method of purification for Gemcitabine hydrochloride to get an ultra pure compound.
The following examples illustrate the specific aspects of the invention. lt should not be misconstrued in limiting the scope of the invention..
Example 1: Preparation of 2-deoxy-2,2-difluoro-D-erythro pento furano-1-ulose- 3,5-diaroyI derivative (Vb)
Ethyl-2,2-difluoro-3-(2,2-dimethyl dioxalan-4-yl) propionate was prepared by the methods described in the literature. The product was rich in R-isomer by about 75% and this product was used in the following reactions
Ethyl-2,2-difluoro-3-(2,2dimethyl dioxalaln-4-yl) propionate 100gms, was charged into a 2 lit four-necked round bottom flask fitted with a stirrer, condenser, dropping funnel and a stopper. Acetonitrile, 1 lit, trifluoroacetic acid 5.0ml and DM water 28ml were also charged into the flask and the reaction mixture was stirred to reflux. The reaction mixture was stirred at reflux temperature for about 3 hours. Then acetonitrile was slowly distilled from the reaction mixture. Simultaneously toluene was charged dropwise into the RB flask at the rate acetonitrile was being distilled off. This process was continued until the mass temperature rose to about 11 O0C and the reaction mixture was stirred at 110 0C for about 15minutes. Later toluene was distilled off completely under reduced pressure at about 60 0C and the residue was used for the next reaction.
The residue, obtained above, was dissolved in ethyl acetate, 500ml and transferred into a 2 lit four-necked flask fitted with a stirrer, condenser carrying a guard tube, an addition funnel carrying a nitrogen bubbling system and a stopper. 4-Dimethyl amino pyridine 10.3gms and pyridine 86ml were charged into the flask. Aroyl chloride, 0'.83 mole was dissolved in 500 ml ethyi acetate and charged into the addition funnel. The reaction mixture was warmed to about 600C to 650C under stirring and the solution of aroyl chloride was added into the flask dropwise in about 3 hours. After the addition, the reaction mixture wis stirred at 60 0C to 65 0C for about 3 hours and then cooled to 250C to 300C and filtered through a bed of hyflow. Then the hyflow bed was washed with 200 ml ethyl acetate. The combained extract was successively washed with 300 ml each of 10%hydrochloric acid, 10% sodium bicarbonate, saturated sodiumchloride solution and finally dried over anhydrous sodium sulphate The ethylacetate solution was filtered and concentrated under reduced pressure. The residue was dissolved in 150 ml toluene and transferred into a three-necked round bottom flask fitted with a stirrer, addition funnel and a thermometer socket. Hexane, 300ml, was charged into the addition funnel and this was added dropwise into the stirred toluene solution. After the addition, the solution was stirred at 25 0C to 30 0C for about 1 hours,, when solid started precipitating out. The reaction mixture was then cooled to about 10 0C to 15 0C and stirred at that temperature for about one hour. The solid was filtered, washed with a mixture of dichloromethane at 60 0C to yield 60.0gms of title compound having the following characteristics.
A) Aroyl= Vb, R= CH3
1H NMR [CDCI3] δ 2.30 (s, 3H1 CH3), 2.35 (s, 3H, CH3), 4.65 (s, 1 H, CH) 5.10 (m, 1 H, CH) 5.9 (m, 2H, CH2) 7.18 (2H, d, J=8Hz, aromatic) 7.22 (2H ,d,J=8Hz,aromatic) 7.75 ( 2H,d,J=8Hz, aromatic) 7.85 (2H,d,J=8Hz, aromatic) IR (KBr): 1830,1736,1711 ,1609,1408,1332,1273,1136 Cm"1
MASS:M+405 MP: 123-1250C, [α]25 D =+ 47° [ c=1.0, CHCI3]
B) Aroyl= Vb1R=NO2
MP: 115-1170C , , [α]25 D = +46.5° [ C=LO1 CHCI3].
1H NMR [CDCi3] δ 2.50 (s, 3H1 CH3), 2.65 (s, 3H, CH3), 4.9 (s, 1 H, CH) 5.10 (m, 1 H1 CH) 6.3 (m, 2H, CH2) 7.2 (2H,d,J=8Hz aromatic) 7.25 (2H,d,J=8Hz, aromatic) 8.2 ( 2H,d.J=8Hz, aromatic) 8.4 ( 2H ,d,J=8Hz, aromatic) IR(KBr): 1839,1744,1720,1615,1412,1339,1281 ,1140 Cm"1 MASS :M+ 469
Example - 2: Preparation of 2-deoxy-2,2-difluoro-D-ribo furanose-3,5-
diaroyl derivative(VIa)
In a 2 lit four-necked round bottom flask with a stirrer, condenser carrying a guard tube, addition funnel carrying a nitrogen inlet system and thermometer socket, was taken 2-deoxy~2,2-difluor.o-D-erythro penta furanose-1-ulose-3,5-diaroyl derevative 100gms, and THF 1 lit. The solution was cooled to about -2O0C under stirring. Vitride 60ml (65% w/w in toluene) was taken in the addition funnel and added dropwise into the flask at such a rate so to maintain the mass temperature at - 20 0C. After the addition, the reactor mixture was stirred at -20 0C for 1 hour. TLC (Mobile phase-Ethyl acetate: Pet. Ether: 2:8) was checked for completion of the reaction. HPLC analysis in zarboax CN using hexane + isopropyl alcohol 92ml + 8ml indicated the product as two peaks. On completion the reaction mixture was allowed to warm upto 0 0C and treated with methanol, 15ml. Later 10% aqueous hydrochloric acid, 300ml, was added into the reaction mass and stirred for 30min. The organic layer was separated. The aqueous layer was extracted with ethyl acetate 500ml. The combined organic layer was washed with 10% NaHCO3 solution, 300ml. The organic layer was separated and then washed with saturated sodium chloride solution, 300ml. Finally organic layer was separated, dried over anhydrousNa2SO4, filtered and concentrated under reduced pressure at 50°Cgave 100 gms crude compound. This was used in the next- stage to prepare the product of formula Via
Example -3: Preparation of 2-deoxy-2,2-difluoro-D-Ribofuranose-3,5-
diaroyl-1-methyl/aryl sulfonate(VIb)
In a 2 lit four-necked round bottom flask fitted with a stirrer, condenser, addition funnel and a thermometer socket, was added the lactol, 100gm, prepared as given in example 2, and toluene, 1 lit. The solution was cooled to 0 0C under stirring and triethyl amine 54ml was added. The solution was stirred at 0 ° , methane sulphonyl/arylsulphonyl chloride 0.28 mol was added dropwise maintaining the mass temperature at 00C. Later the reaction mass was allowed to warm upto 200C to 25 0C and stirred further for 12-14hours. The reaction mixture was analyzed byTLC (Mobile phase-Ethyl acetate: Pet. Ether: 2:8). It was also analyzed by HPLC in zarboax CN using hexane + isopropyl alcohol 92ml + 8ml which indicated the product as two peaks. The reaction mixture was washed with 5% aqueous sodium bicarbonate solution, 325ml, saturated sodium chloride solution 325ml and separated. The toluene extract was dried over anhydrous sodium sulphate, filtered and then concentrated to give 100 gms of the title product. This was used for the Verbruggen protocol. Example- 4: Preparation of 2'-Deoxy-2',2'-difluoro cytidine(I) In a 5 lit three-necked round bottom flask fitted with a stirrer, condenser and a stopper, acetyl cytosine 97.36gms, toluene 2lit, hexamethyl disilazane 169ml and trimethyl silyl chloride 5ml were charged and the reaction mixture was heated to reflux under stirring. The reaction mixture slowly attained clarity and from that point the mixture was stirred at reflux for another 3 hours. Then toluene was completely distilled off and fresh toluene 1250ml, was charged into the flask and the reaction mixture was cooled to 20 0C to 25 0C. The reaction system was maintained under nitrogen atmosphere and trimethyl silyl trifluoromethane sulfonate, 113ml, was added. Then 2-deoxy-2,2-difluoro-D-ribofuranose-3,5-diaroyl, -1 -methane/ aryl sulfonate, 100gm, was also added into the flask. The reaction mixture was heated to 70 0C to 75 0C and maintained for 12-14 hours. Subsequently the reaction mixture was stirred under reflux for 2 hours. The progress of the reaction was monitored by TLC (dichloromethane: methanol 9:1). The reaction mixture was cooled to 200C to 25 0C and 5% aqueous hydrochloric acid, 600ml, was added dropwise in about 30minutes. After the addition, the reaction mixture was stirred for 15minutes and allowed the layers to separate. The aqueous layer was washed with toluene 2000ml and the combined toluene 9 extract was washed with a saturated solution of sodium chloride, 300ml. Then the organic layer was separated and dried with anhydrous sodium sulphate. The fluoro benzene solution was filtered and concentrated under reduced pressure at 50 0C. the residue was dissolved in 1.5lit methanol and cooled to about 0 0C to 5 0C. Ammonia gas was bubbled into the methanolic solution for about 8 hours. Then the solution was brought to about 200C to 250C and ammonia gas was bubbled for further 8 hours. The progress of the reaction reaction was monitored by TLC for completion. The methanolic solution was treated with carbon, 15gms and filtered. The filtrate was concentrated under reduced pressure at 450C. The residue was dissolved in about 400ml Water and the aqueous solution was washed first with 100ml ethyl acetate and then with 100ml hexane . The ethyl acetate and hexane extracts were separately washed with 50ml each of water and the water extracts were combined with the main aqueous solution. The aqueous extract was stirred with carbon, 10gm, and filtered through a bed of hyflow.The hyflow bed was washed with water, 50ml. The combined aqueous solution was then concentrated. The residue was dissolved in 1500ffil isopropyl alcohol and then the solution was subjected to distillation. The addition of isopropyl alcohol and distillation was repeated two more times by adding 750ml of alcohol each time. Finally isopropyl alcohol, 700ml, was added to the residue and the solution was warmed to about 70 0C. To the warm aqueous isopropyl alcohol, concentrated hydrochloric acid 75ml was added dropwise in about 30min. The solution was stirred at 70 0C to 75 0C for about 30min, then cooled to RT and stirred for 12 hours. Later the solution was cooled to 00C to 50C, stirred at that temperature for 3 hours, the solid formed was filtered, washed with acetone and dried to give 10.0 gm of product, which was >95% rich in the β-anomer and showed [α]D 26 = +46° (C=LO1 D 2O)
Example - 5: Purification of 2'-deoxy-2',2'-difluoro cytidine(l)
Method A: About 50gms of the product of about 95% rich in β-anomer was stirred with 50ml DM water at 30 0C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give40.0 gm of product.
The solid obtained above was taken in about 188 ml water in a 250 ml three- necked round bottom flask fitted with a stirrer, condenser and a stopper. The slurry was heated to 700C to 750C in order to dissolve the solid: The solution was filtered to remove any insoluble material and the filtrate was transferred into a 3 lit three- necked flask fitted with a stirrer, addition funnel and stopper. The aqueous solution was stirred at 25 0C to 30 0C and acetone2.3 lit, was added dropwise from the addition funnel. After the completion of addition the slurry was stirred at 250C to 3.0 0C for 1 hour and the solid was filtered. It was washed'with acetone and dried at 60 0C to give 36.0 gm of very pure product.
HPLC 99.9%, [α]D 25 = + 47° (c=1.0, D 2O)
Method B: About 50gms of the product of about 95% rich in β-anomer, was stirred with 50ml DM water at 30 0C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give gms of product
The solid obtained above was taken in about 190 ml of water in a 250 ml three-necked round bottom flask fitted with a stirrer, condenser and a stopper. The slurry was heated to about 700C to 750C in order to dissolve the solid. The solution was filtered to remove any insoluble material and the filtrate was transferred into a 3lit three-necked round bottom flask fitted with a stirrer, addition funnel and stopper. The aqueous solution was stirred at 250C to 300C and 3 lit acetonitrile was added dropwise from the addition funnel. After the completion of addition the slurry was stirred at 250C to 3O 0C and the solid was filtered, washed with acetone, pressed dry and dried 60 0C to give 36 gm of very pure product.
HPLC 99.92%, [α]D 25 =+ 47° (c= 1.0, D 2O)
Method C: About 50gms of the product about 95% rich β-anomer was stirred with 50ml DM water at 30 0C for about 30minutes in a 250ml three-necked round bottom flask. The solid material was filtered, washed with acetone and pressed dry to give 40 gm of product.
The solid obtained above was later dissolved in about 188 ml water in a 250 ml three-necked round bottom flask fitted with a stirrer, condenser and a stopper. The slurry was heated to about 700C to 750C^n order to dissolve the solid. The solution was filtered to remove any insoluble material and the filtrate was transferred into a 3 lit three necked round bottom flask fitted with a stirrer, addition funnel and stopper. The aqueous solution was stirred at 250C to 300C and isopropyl alcohol 2.3 lits was added dropwise from the addition funnel. After completion of addition, the slurry was stirred at 25 0C to 30 0C for one hour and the solid was filtered, washed with first with isopropyl alcohol, then with acetone and dried at 60 0C to give 36 gms ofvery pure product.
HPLC 99.92%, [α]D 25 = + 47° (c= 1.0, D2O)

Claims

1. A process for the synthesis of hereto unreported novel intermediates VIZ 2-deoxy-2,2-difiuoro-D-ribofuranose-3,5-di (aroyl) derivative of formula - VbI, where is R=CH31CI1NO2 as described earlier, and its conversion to gemcitabine HCI of formual - I.
2. A claim, as claimed in claim 1 , wherein the dibenzoate of formula - Vb is prepared by reacting 2-deoxy-2,2-di f!uoro-1-oxo ribose of formula -VII with aroyl chloride in an organic solvent in the presence of an organic base as an acid scavenging agent and a promoter at a temperature of 0 - 1000 C.
3. A claim, as claimed in claim 2, wherein the acid chloride used are A- methyl benzoyl chloride, 4-nitro benzoyl chloride and 4-chloro benzoyl chloride.
4. A claim, as claimed in claim 2, wherein the reaction is conducted in ethyl acetate, isopropyl acetate, butyl acetate.
5. A claim, as claimed in claim 2, wherein the organic base used is pyridine, α-picoline, β-picoline, γ-picoline a mixture of picolines etc.
6. A claim, as claimed in claim 2, wherein the promoter used is 4-dimethyl amino pyridine.
7. A claim, as claimed in claim2, wherein the reaction is conducted at a temperature of 50 - 70° C, preferably 60 - 65° C.
8. A claim, as claimed in claim 2, wherein the aroyl derivative of formula - Vb, where R is as given earlier, is isolated in pure form (98 - 99 % HPLC) by crystallizing from a mixture of toluene/hexane, or heptane or petroleum ether.
9. A claim, as claimed in claim 1 , wherein the aroyl derivative of formula - Vb, where R is as described earlier, is converted to gemcitabine HCI of formula - i by a) reducing the product of formula - Vb, to give a product of formula - Via, where R is as described earlier, b) converting the product of formula - Via to a product of formula - VIb, were R is as described earlier c) coupling the .product of formula - VIb with disilylated product of formula - Xl d) hydrolyzing and e) purifying
10. A claim, as claimed in claim 9a, wherein the reduction is carried out using VITRIDE in toluene, THF, dioxane, monoglyme, diglyme, etc at - 30 to +300 C.
11. A claim, as claimed in claim 9b, wherein product of formula - Via is converted to a product of formula - VIb, by reacting with alkyl or aryl sulphonyl chloride wherein alkyl/aryl sulphonyl chloride is methane sulphonyl chloride.benzene sulphonyl chloride. p-toluene sulphonyl chloride in dichloro methane or ethyl acetate in the presence of a acid scavenging agent like tri ethyl amine or diiso propyl ethyl amine or N-methyl morpholine at 0 - 50° C.
12. A claim, as claimed in claim 9c, wherein the product of formula - VIb is coupled with the silylated product of formula - Xl in a solvent like toluene, fluoro benzene di chloro ethane, ethylacetate and acetonitrile using tri methyl silyl tri .fluoro methane sulfonate at 60 - 65° C for a duration of 8 to 24 hours.
13. A claim, as claimed in claim 9d, wherein the product formed after coupling of products of formula - VIb and Xl respectively was treated with ammonia or dimethyl amine or diethylamine in anhydrous alcohols like methanol, ethanol, l-propanol or 2-propanol at 0 - 5° C.
14. - A claim, as claimed in claim 9d, wherein ,,-|he hydrolyzed product was purified by, a) isolation of the crude gemcitabin HCI in aqueous isopropanolic hydrochloric acid b) leaching the crude product with water c) crystallizing the water leached product in aqueous organic solvents like ethanol, 2-propanol or acetonitrile or acetone.
PCT/IN2005/000160 2005-03-10 2005-05-19 Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof Ceased WO2006095359A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN240CH2005 2005-03-10
IN240/CHE/2005 2005-03-10

Publications (1)

Publication Number Publication Date
WO2006095359A1 true WO2006095359A1 (en) 2006-09-14

Family

ID=36952990

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000160 Ceased WO2006095359A1 (en) 2005-03-10 2005-05-19 Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof

Country Status (1)

Country Link
WO (1) WO2006095359A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117955A1 (en) * 2007-03-23 2008-10-02 Dongwoo Syntech Co., Ltd. Process for preparing of 2'-deoxy-2'2'-difluorocytidine
KR100863463B1 (en) * 2007-03-23 2008-10-16 동우신테크 주식회사 Method for preparing optically pure oxo ribose derivative
ITMI20081874A1 (en) * 2008-10-23 2010-04-24 Prime Europ Therapeuticals PROCEDURE FOR THE PREPARATION OF GEMCITABINE CHLORIDRATE
EP1960378A4 (en) * 2005-12-14 2011-05-25 Dong A Pharm Co Ltd A manufacturing process of 2',2'-difluoronucleoside and intermediate
CN102617484A (en) * 2011-06-30 2012-08-01 江苏豪森药业股份有限公司 Process for recycling cytosine during preparing process of gemcitabine hydrochloride
CN102617483A (en) * 2011-06-30 2012-08-01 江苏豪森药业股份有限公司 Process for recycling cytosine during preparing process of gemcitabine hydrochloride
CN102659884A (en) * 2012-04-23 2012-09-12 南京臣功制药股份有限公司 Gemcitabine hydrochloride purifying method
CN103980333A (en) * 2014-05-23 2014-08-13 上海鼎雅药物化学科技有限公司 Method for purifying gemcitabine hydrochloride
CN107200757A (en) * 2017-06-29 2017-09-26 上海泓博智源医药股份有限公司 A kind of bridged ring fluoroester and its preparation method and application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719788A2 (en) * 1994-12-13 1996-07-03 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2',2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one) hydrochloride

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0719788A2 (en) * 1994-12-13 1996-07-03 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2',2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one) hydrochloride

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOU T.S. ET AL.: "Stereospecific Synthesis of 2-Deoxy-2,2-difluororibonolactone and Ist Use in the Preparation of 2-Deoxy-2,2-difluoro-beta-D-ribofuranosyl Pyrimidine Nucleosides: The Key Role of Selective Crystallization", SYNTHESIS, June 1992 (1992-06-01), pages 565 - 570, XP000572747, DOI: doi:10.1055/s-1992-26167 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1960378A4 (en) * 2005-12-14 2011-05-25 Dong A Pharm Co Ltd A manufacturing process of 2',2'-difluoronucleoside and intermediate
KR100863463B1 (en) * 2007-03-23 2008-10-16 동우신테크 주식회사 Method for preparing optically pure oxo ribose derivative
US7994310B2 (en) 2007-03-23 2011-08-09 Dongwoo Syntech Co., Ltd. Process for preparing 2′-deoxy-2′, 2′-difluorocytidine
WO2008117955A1 (en) * 2007-03-23 2008-10-02 Dongwoo Syntech Co., Ltd. Process for preparing of 2'-deoxy-2'2'-difluorocytidine
JP2010522158A (en) * 2007-03-23 2010-07-01 ドンウ シンテック カンパニー リミテッド Method for producing 2'-deoxy-2 ', 2'-difluorocytidine
EP2180005A1 (en) * 2008-10-23 2010-04-28 Prime European Therapeuticals S.p.A. in forma Abbreviata Euticals S.p.A. Process for the preparation of gemcitabine chlorohydrate
ITMI20081874A1 (en) * 2008-10-23 2010-04-24 Prime Europ Therapeuticals PROCEDURE FOR THE PREPARATION OF GEMCITABINE CHLORIDRATE
US8299239B2 (en) 2008-10-23 2012-10-30 Prime European Therapeucials S.p.A. Process for the preparation of gemcitabine hydrochloride
CN102617484A (en) * 2011-06-30 2012-08-01 江苏豪森药业股份有限公司 Process for recycling cytosine during preparing process of gemcitabine hydrochloride
CN102617483A (en) * 2011-06-30 2012-08-01 江苏豪森药业股份有限公司 Process for recycling cytosine during preparing process of gemcitabine hydrochloride
CN102659884A (en) * 2012-04-23 2012-09-12 南京臣功制药股份有限公司 Gemcitabine hydrochloride purifying method
CN103980333A (en) * 2014-05-23 2014-08-13 上海鼎雅药物化学科技有限公司 Method for purifying gemcitabine hydrochloride
CN107200757A (en) * 2017-06-29 2017-09-26 上海泓博智源医药股份有限公司 A kind of bridged ring fluoroester and its preparation method and application

Similar Documents

Publication Publication Date Title
EP3172218B1 (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
KR102695300B1 (en) Synthesis of phosphate derivatives
KR20180101370A (en) Selective Synthesis of Diastereomers of Phosphate Derivatives and Gemcitabine Prodrug NUC-1031
JP3653292B2 (en) Mass production of 2 ', 3'-didehydro-3'-deoxythymidine (d4T) using 5-methyluridine
WO2020165334A1 (en) Process for preparing 3'-o-amino-ribonucleotide
WO2006095359A1 (en) Synthesis of 2-deoxy-2, 2-di fluoro-d-ribo furanose-3, 5 di(4-methy/4-nitro-chloro)benzoate and its conversion to gemcitabine hydrochloride thereof
US20130018181A1 (en) Novel and Highly Stereoselective Process for Preparing Gemcitabine and Intermediates Thereof
WO2005095430A1 (en) An improved process for the manufacture of high pure gemcitabine hydrochloride
CN101203524A (en) Intermediates and methods for the preparation of β-anomer enriched 21-deoxy,21,21-difluoro-D-ribofuranucleosides
US8193354B2 (en) Process for preparation of Gemcitabine hydrochloride
CA2168080C (en) Process for the preparation of 1-(2'-deoxy-2',2'-difluoro- d-ribopentofuranosyl)-cytosine from 2-deoxy-2,2-difluoro- beta-d-ribo-pentopyranose
JPH051092A (en) Nucleoside derivative and its production
CN116554237B (en) Preparation method and application of fluoro ribose intermediate
JPH08269081A (en) Method for producing 3,3-difluorofuran in which the 2-position is substituted
US20030236397A1 (en) Process for preparing beta-L-2'deoxy-thymidine
CN1263765C (en) Process for prepn. of cytidine derivatives
CN1982301B (en) 2', 2'-difluoronucleoside and preparation method of its intermediate
JP2770357B2 (en) Method for producing nucleoside derivative
KR102920287B1 (en) Synthesis of phosphate derivatives
JP2002293792A (en) Method for producing nucleoside or fluorinated sugar derivative
CN117700369A (en) Preparation method of 2- (2-chloropyrimidine-5-yl) acetic acid/ester
HK1232546A1 (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
HK1232546B (en) Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
JPH06135989A (en) Nucleotide derivative
JPH0656878A (en) Guanosine derivative, its production and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 05750180

Country of ref document: EP

Kind code of ref document: A1

WWW Wipo information: withdrawn in national office

Ref document number: 5750180

Country of ref document: EP